Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting

被引：5
|
作者：
Hobbs, Miriam [1 ]
Paludo, Jonas [1 ]
Fonder, Amie [1 ]
Abeykoon, Jithma P. [2 ]
Gertz, Morie A. [1 ]
Rajkumar, S. Vincent [1 ]
Go, Ronald S. [1 ]
Buadi, Francis K. [1 ]
Lacy, Martha Q. [1 ]
Leung, Nelson [1 ]
Dispenzieri, Angela [1 ]
Gonsalves, Wilson I. [1 ]
Dingli, David [1 ]
Hwa, Yi L. [1 ]
Kourelis, Taxiarchis [1 ]
Kyle, Robert A. [1 ]
Kumar, Shaji [1 ]
Kapoor, Prashant [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Internal Med, Rochester, MN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3337.3337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3337
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Sher, Taimur
    Paulus, Aneel
    Chapin, Dustin
    Heslop, Keisha
    Chanan-Khan, Asher
    Roy, Vivek
    BLOOD, 2022, 140 : 4450 - 4451
  • [42] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
    Juan Du
    Baijun Fang
    Jian Li
    Jie Jin
    Shunqing Wang
    Dehui Zou
    Zhen Cai
    Hongxiang Wang
    Jianda Hu
    Wei Li
    Chengcheng Fu
    Zonghong Shao
    Zhongjun Xia
    Peng Liu
    Ting Niu
    En-Tzu Tang
    Amy S. Kimball
    Jian Hou
    Wenming Chen
    International Journal of Hematology, 2021, 113 : 422 - 429
  • [43] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
  • [44] Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma
    Jandial, Aditya
    Mishra, Kundan
    Lad, Deepesh
    Prakash, Gaurav
    Khadwal, Alka
    Malhotra, Pankaj
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 1102 - 1104
  • [45] Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
    Cohen, Alexa
    Spektor, Tanya M.
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall
    Eshaghian, Shahrooz
    Nassir, Youram
    Maluso, Tina
    Swift, Regina A.
    Vescio, Robert
    Berenson, James R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 60 - 70
  • [46] EFFICACY AND TOLERABILITY OF LENOLIDOMIDE AND POMALIDOMIDE IN RELAPSED/ REFRACTORY MYELOMA PATIENTS IN A REAL WORLD STUDY
    Adams, G.
    Collins, M.
    Kyriakou, C.
    Ayto, R.
    HAEMATOLOGICA, 2017, 102 : 787 - 787
  • [47] CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Ri, M.
    Suzuki, K.
    Chou, T.
    Sugiura, I.
    Takezako, N.
    Sunami, K.
    Ishida, T.
    Izumi, T.
    Ozaki, S.
    Iida, S.
    HAEMATOLOGICA, 2016, 101 : 787 - 788
  • [48] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
    Du, Juan
    Fang, Baijun
    Li, Jian
    Jin, Jie
    Wang, Shunqing
    Zou, Dehui
    Cai, Zhen
    Wang, Hongxiang
    Hu, Jianda
    Li, Wei
    Fu, Chengcheng
    Shao, Zonghong
    Xia, Zhongjun
    Liu, Peng
    Niu, Ting
    Tang, En-Tzu
    Kimball, Amy S.
    Hou, Jian
    Chen, Wenming
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 422 - 429
  • [49] Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials.
    Paul, Barry
    Robinson, Myra M.
    Robinson, Jordan
    Ndiaye, Ami
    Bhutani, Manisha
    Voorhees, Peter Michael
    Symanowski, James Thomas
    Friend, Reed N.
    Pineda-Roman, Mauricio
    Usmani, Saad Zafar
    Atrash, Shebli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Moon, Joon-Ho
    Ng, Soo Chin
    Park, Sung Soo
    Koh, Youngil
    Lee, Ji Hyun
    Eom, Hyeon-Seok
    Shin, Ho-Jin
    Lee, Je-Jung
    Do, Young Rok
    Wilfred, Gilbert
    Husin, Azlan
    Kim, Hyo Jung
    Wahid, S. Fadilah Abdul
    Lee, Myung-Won
    Heo, Hye-won
    Kim, Kihyun
    Chuncharunee, Suporn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S263 - S264
12345